Mrs Shira Khoshkerman, PA-C | |
17200 Ventura Blvd Ste 302, Encino, CA 91316-5008 | |
(818) 905-8815 | |
Not Available |
Full Name | Mrs Shira Khoshkerman |
---|---|
Gender | Female |
Speciality | Physician Assistant - Medical |
Location | 17200 Ventura Blvd Ste 302, Encino, California |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063923738 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208M00000X | Hospitalist | C0006666 (Maryland) | Secondary |
363AM0700X | Physician Assistant - Medical | PA58912 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Shira Khoshkerman, PA-C 17200 Ventura Blvd Ste 302, Encino, CA 91316-5008 Ph: () - | Mrs Shira Khoshkerman, PA-C 17200 Ventura Blvd Ste 302, Encino, CA 91316-5008 Ph: (818) 905-8815 |
News Archive
As the Food and Drug Administration (FDA) mulls over whether to rein in the use of common antibacterial compounds that are causing growing concern among environmental health experts, scientists are reporting today that many pregnant women and their fetuses are being exposed to these substances.
Researchers in Australia have shown that positron emission tomography (PET) that uses a radioactive sugar molecule is more useful than mammography and ultrasound in predicting a breast tumour's response to chemotherapy and, therefore, the patient's ultimate likelihood of survival.
Women who undergo weight-loss surgery, known as bariatric surgery, and later become pregnant after losing weight may be at lower risk for pregnancy-related diabetes and high blood pressure - complications that can seriously affect the mother or her baby - than pregnant women who are obese, according to new findings from the Agency for Healthcare Research and Quality that are published in the November 19 issue of JAMA.
Ellipse Technologies, Inc. announced today it has received CE Mark (Conformité Européenne) for its MAGECTM Technology for the treatment of spinal deformity. The first application for this technology is for the treatment of spinal scoliosis in young children and teenagers. The CE Mark allows the Company to market the MAGEC System in the European Union and other countries that recognize the CE Mark for commercial distribution purposes.
› Verified 8 days ago